THE PFIZER DOCUMENTS PART 1 3/22/22

Alert: This is only a four minute read really. You'll see why at the end.

So many of you may remember the big stink back in November of 2021 when the FDA, a government body whose mission statement is (bolding or caps mine for emphasis) “protecting consumers and enhancing public health by maximizing compliance of FDA regulated products and minimizing risk associated with those products.” petitioned the courts in response to a Freedom of Information Act (FOIA) request to allow them 55 YEARS (maybe 75 years) to release the data on the vax. Lawyers from the “Justice Department” (whose “justice” exactly?) who represented the FDA said the FOIA request was for more than 300,000 pages so 55 YEARS seemed about right to them. 55 YEARS.

According to Reuters “The FDA proposes releasing 500 pages per month on a rolling basis, noting that the branch that would handle the review has only 10 employees and is currently processing about 400 other FOIA requests.” The FDA has over 18,000 employees but can only spare 10 to work on releasing to the American people the information on a product that they’ve shoved down our throats? Only 10 employees to find out what we did to ourselves taking a vaccine we paid for which was approved for use by a government organization that we pay for? Well, actually, we only pay about 54% of the FDA’s budget; the drug companies pay the other 46%, which couldn’t possibly cause a conflict. Fox…meet henhouse.

But “Plaintiffs' lawyers argue that their request should be top priority, and that the FDA should release all the material no later than March 3, 2022…‘This 108-day period is the SAME AMOUNT OF TIME it took the FDA to review the responsive documents for the far more intricate task of licensing Pfizer’s COVID-19 vaccine,’” so there’s that.

Anyway, the first tranche (my new favorite word) of documents has been released; tens of thousands of pages and it’ll be interesting to see what comes of it. Something? Nothing? Who knows?

But just in this one particular document entitled “5.3.6 CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021” when discussing adverse effects of the vaccine we read:

“Pfizer has also taken a (sic) multiple actions to help alleviate the large increase of adverse event reports. This includes significant technology enhancements, and process and workflow solutions, as well as increasing the number of data entry and case processing colleagues. To date, Pfizer has onboarded approximately (b) (4) additional full time employees (FTEs). More are joining each month with an expected total of more than (b) (4) additional resources by the end of June 2021.”

“It is estimated that approximately (b) (4) doses of BNT162b2 were shipped worldwide

from the receipt of the first temporary authorisation for emergency supply on 01 December 2020 through 28 February 2021…Cumulatively, through 28 February 2021, there was a total of 42,086 case reports...”

The “(b) (4)” are numbers that have evidently been redacted. So my questions are:

Why exactly would the FDA want 55 years to release this information which is clearly of significant interest to the American people? The "only 10 employees" thing ain't cuttin' it.

Why exactly would Pfizer hide how many vaccines had been administered? Why exactly would the courts allow this? We are told “…the FDA can’t simply turn the documents over wholesale. The records must be reviewed to redact ‘confidential business and trade secret information of Pfizer or BioNTech and personal privacy information of patients who participated in clinical trials,’” Now if they’re redacting say, Coke’s secret formula or the Colonel’s 11 herbs and spices or even whatever Victoria’s secret actually is, well then I get it. But how does the number of vaccines administered or how many people Pfizer has to hire to handle the influx of adverse effects reports fall under the rubric of “confidential business and trade secret information”? Bueller? Bueller? I’ll leave that one to your imagination.

Through other measures we can get a rough estimate of about 80 million doses administered during this initial three month period. Now that wouldn’t be 80 million separate people, some people would’ve only had one dose while others would’ve gotten two doses during this time. So let’s take an average and assume some 60 million individuals were vaccinated (either one shot or two) during this time. That leaves us with an adverse event ratio of about 1 in every 1,400 shots, or about 0.07% (seven one-hundredths of one percent). Now if you’ve been following along, or just read my previous post on Germany and vax events found here https://www.springfieldholisticwellness.com/blog you’ll know that adverse event numbers are woefully under-reported. But let’s take it at face value. As I try to always be consistent, I will say here that 0.07% doesn’t seem much to be concerned about, especially as many of these adverse events are pretty run-of-the-mill things like arm soreness or transient fever, so what’s with the hiding the numbers?

Who knows? Can’t say. But the same way I and others insisted that anyone who told you they “knew” the vaccine was “safe and effective” was lying – it was IMPOSSIBLE to know if it was either – and has since shown to be neither, I now raise the possibility that there’s more we’re not being told. Things that Pfizer and the government know. Things that might not have been in our best interests. Just in this one document we can see both the government and Pfizer lying. Who knows what we’ll find out as more documents are released and analyzed. Suffice it to say that if you are still a true believer, you’re lost.

While I’m writing this post, someone just sent me an article warning about the next boogeyman, the Omicron BA.2, also known as the Stealth Variant!! The names keep getting cooler. She was concerned (the point of the PANIC PORN) and wanted to know what I thought. My response: More PANIC PORN. You have about six months to get healthier so whatever nonsense comes next fall, you’ll be protected by your own God-given natural ability to defeat the evil Stealth Variant. Get to work.

By the way, I was going to list some of the noted adverse events within the first three months of the vax rollout, but thought it was easier just to cut and paste the whole list. To be clear, not all of these are necessarily due to the vax, but they made the list. Here you go:

APPENDIX 1. LIST OF ADVERSE EVENTS OF SPECIAL INTEREST

1p36 deletion syndrome;2-Hydroxyglutaric aciduria;5'nucleotidase increased;Acoustic

neuritis;Acquired C1 inhibitor deficiency;Acquired epidermolysis bullosa;Acquired epileptic

aphasia;Acute cutaneous lupus erythematosus;Acute disseminated encephalomyelitis;Acute

encephalitis with refractory, repetitive partial seizures;Acute febrile neutrophilic

dermatosis;Acute flaccid myelitis;Acute haemorrhagic leukoencephalitis;Acute

haemorrhagic oedema of infancy;Acute kidney injury;Acute macular outer retinopathy;Acute

motor axonal neuropathy;Acute motor-sensory axonal neuropathy;Acute myocardial

infarction;Acute respiratory distress syndrome;Acute respiratory failure;Addison's

disease;Administration site thrombosis;Administration site vasculitis;Adrenal

thrombosis;Adverse event following immunisation;Ageusia;Agranulocytosis;Air

embolism;Alanine aminotransferase abnormal;Alanine aminotransferase increased;Alcoholic

seizure;Allergic bronchopulmonary mycosis;Allergic oedema;Alloimmune

hepatitis;Alopecia areata;Alpers disease;Alveolar proteinosis;Ammonia abnormal;Ammonia

increased;Amniotic cavity infection;Amygdalohippocampectomy;Amyloid

arthropathy;Amyloidosis;Amyloidosis senile;Anaphylactic reaction;Anaphylactic

shock;Anaphylactic transfusion reaction;Anaphylactoid reaction;Anaphylactoid

shock;Anaphylactoid syndrome of pregnancy;Angioedema;Angiopathic

neuropathy;Ankylosing spondylitis;Anosmia;Antiacetylcholine receptor antibody

positive;Anti-actin antibody positive;Anti-aquaporin-4 antibody positive;Anti-basal ganglia

antibody positive;Anti-cyclic citrullinated peptide antibody positive;Anti-epithelial antibody

positive;Anti-erythrocyte antibody positive;Anti-exosome complex antibody positive;Anti-

GAD antibody negative;Anti-GAD antibody positive;Anti-ganglioside antibody

positive;Antigliadin antibody positive;Anti-glomerular basement membrane antibody

positive;Anti-glomerular basement membrane disease;Anti-glycyl-tRNA synthetase antibody

positive;Anti-HLA antibody test positive;Anti-IA2 antibody positive;Anti-insulin antibody

increased;Anti-insulin antibody positive;Anti-insulin receptor antibody increased;Antiinsulin

receptor antibody positive;Anti-interferon antibody negative;Anti-interferon antibody

positive;Anti-islet cell antibody positive;Antimitochondrial antibody positive;Anti-muscle

specific kinase antibody positive;Anti-myelin-associated glycoprotein antibodies

positive;Anti-myelin-associated glycoprotein associated polyneuropathy;Antimyocardial

antibody positive;Anti-neuronal antibody positive;Antineutrophil cytoplasmic antibody

increased;Antineutrophil cytoplasmic antibody positive;Anti-neutrophil cytoplasmic

antibody positive vasculitis;Anti-NMDA antibody positive;Antinuclear antibody

increased;Antinuclear antibody positive;Antiphospholipid antibodies

positive;Antiphospholipid syndrome;Anti-platelet antibody positive;Anti-prothrombin

antibody positive;Antiribosomal P antibody positive;Anti-RNA polymerase III antibody

positive;Anti-saccharomyces cerevisiae antibody test positive;Anti-sperm antibody

positive;Anti-SRP antibody positive;Antisynthetase syndrome;Anti-thyroid antibody

positive;Anti-transglutaminase antibody increased;Anti-VGCC antibody positive;Anti-

VGKC antibody positive;Anti-vimentin antibody positive;Antiviral prophylaxis;Antiviral

treatment;Anti-zinc transporter 8 antibody positive;Aortic embolus;Aortic

thrombosis;Aortitis;Aplasia pure red cell;Aplastic anaemia;Application site

thrombosis;Application site vasculitis;Arrhythmia;Arterial bypass occlusion;Arterial bypass

thrombosis;Arterial thrombosis;Arteriovenous fistula thrombosis;Arteriovenous graft site

stenosis;Arteriovenous graft thrombosis;Arteritis;Arteritis

Page 30 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (

GMT)

FDA-CBER-2021-5683-0000083

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

CONFIDENTIAL

Page 2

coronary;Arthralgia;Arthritis;Arthritis enteropathic;Ascites;Aseptic cavernous sinus

thrombosis;Aspartate aminotransferase abnormal;Aspartate aminotransferase

increased;Aspartate-glutamate-transporter deficiency;AST to platelet ratio index

increased;AST/ALT ratio abnormal;Asthma;Asymptomatic COVID-

19;Ataxia;Atheroembolism;Atonic seizures;Atrial thrombosis;Atrophic thyroiditis;Atypical

benign partial epilepsy;Atypical pneumonia;Aura;Autoantibody positive;Autoimmune

anaemia;Autoimmune aplastic anaemia;Autoimmune arthritis;Autoimmune blistering

disease;Autoimmune cholangitis;Autoimmune colitis;Autoimmune demyelinating

disease;Autoimmune dermatitis;Autoimmune disorder;Autoimmune

encephalopathy;Autoimmune endocrine disorder;Autoimmune enteropathy;Autoimmune eye

disorder;Autoimmune haemolytic anaemia;Autoimmune heparin-induced

thrombocytopenia;Autoimmune hepatitis;Autoimmune hyperlipidaemia;Autoimmune

hypothyroidism;Autoimmune inner ear disease;Autoimmune lung disease;Autoimmune

lymphoproliferative syndrome;Autoimmune myocarditis;Autoimmune myositis;Autoimmune

nephritis;Autoimmune neuropathy;Autoimmune neutropenia;Autoimmune

pancreatitis;Autoimmune pancytopenia;Autoimmune pericarditis;Autoimmune

retinopathy;Autoimmune thyroid disorder;Autoimmune thyroiditis;Autoimmune

uveitis;Autoinflammation with infantile enterocolitis;Autoinflammatory disease;Automatism

epileptic;Autonomic nervous system imbalance;Autonomic seizure;Axial

spondyloarthritis;Axillary vein thrombosis;Axonal and demyelinating

polyneuropathy;Axonal neuropathy;Bacterascites;Baltic myoclonic epilepsy;Band

sensation;Basedow's disease;Basilar artery thrombosis;Basophilopenia;B-cell

aplasia;Behcet's syndrome;Benign ethnic neutropenia;Benign familial neonatal

convulsions;Benign familial pemphigus;Benign rolandic epilepsy;Beta-2 glycoprotein

antibody positive;Bickerstaff's encephalitis;Bile output abnormal;Bile output

decreased;Biliary ascites;Bilirubin conjugated abnormal;Bilirubin conjugated

increased;Bilirubin urine present;Biopsy liver abnormal;Biotinidase deficiency;Birdshot

chorioretinopathy;Blood alkaline phosphatase abnormal;Blood alkaline phosphatase

increased;Blood bilirubin abnormal;Blood bilirubin increased;Blood bilirubin unconjugated

increased;Blood cholinesterase abnormal;Blood cholinesterase decreased;Blood pressure

decreased;Blood pressure diastolic decreased;Blood pressure systolic decreased;Blue toe

syndrome;Brachiocephalic vein thrombosis;Brain stem embolism;Brain stem

thrombosis;Bromosulphthalein test abnormal;Bronchial oedema;Bronchitis;Bronchitis

mycoplasmal;Bronchitis viral;Bronchopulmonary aspergillosis allergic;Bronchospasm;Budd-

Chiari syndrome;Bulbar palsy;Butterfly rash;C1q nephropathy;Caesarean section;Calcium

embolism;Capillaritis;Caplan's syndrome;Cardiac amyloidosis;Cardiac arrest;Cardiac

failure;Cardiac failure acute;Cardiac sarcoidosis;Cardiac ventricular thrombosis;Cardiogenic

shock;Cardiolipin antibody positive;Cardiopulmonary failure;Cardio-respiratory

arrest;Cardio-respiratory distress;Cardiovascular insufficiency;Carotid arterial

embolus;Carotid artery thrombosis;Cataplexy;Catheter site thrombosis;Catheter site

vasculitis;Cavernous sinus thrombosis;CDKL5 deficiency disorder;CEC syndrome;Cement

embolism;Central nervous system lupus;Central nervous system vasculitis;Cerebellar artery

thrombosis;Cerebellar embolism;Cerebral amyloid angiopathy;Cerebral arteritis;Cerebral

artery embolism;Cerebral artery thrombosis;Cerebral gas embolism;Cerebral

microembolism;Cerebral septic infarct;Cerebral thrombosis;Cerebral venous sinus

thrombosis;Cerebral venous thrombosis;Cerebrospinal thrombotic

Page 31 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (

GMT)

FDA-CBER-2021-5683-0000084

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

CONFIDENTIAL

Page 3

tamponade;Cerebrovascular accident;Change in seizure presentation;Chest discomfort;Child-

Pugh-Turcotte score abnormal;Child-Pugh-Turcotte score

increased;Chillblains;Choking;Choking sensation;Cholangitis sclerosing;Chronic

autoimmune glomerulonephritis;Chronic cutaneous lupus erythematosus;Chronic fatigue

syndrome;Chronic gastritis;Chronic inflammatory demyelinating

polyradiculoneuropathy;Chronic lymphocytic inflammation with pontine perivascular

enhancement responsive to steroids;Chronic recurrent multifocal osteomyelitis;Chronic

respiratory failure;Chronic spontaneous urticaria;Circulatory collapse;Circumoral

oedema;Circumoral swelling;Clinically isolated syndrome;Clonic convulsion;Coeliac

disease;Cogan's syndrome;Cold agglutinins positive;Cold type haemolytic

anaemia;Colitis;Colitis erosive;Colitis herpes;Colitis microscopic;Colitis ulcerative;Collagen

disorder;Collagen-vascular disease;Complement factor abnormal;Complement factor C1

decreased;Complement factor C2 decreased;Complement factor C3 decreased;Complement

factor C4 decreased;Complement factor decreased;Computerised tomogram liver

abnormal;Concentric sclerosis;Congenital anomaly;Congenital bilateral perisylvian

syndrome;Congenital herpes simplex infection;Congenital myasthenic syndrome;Congenital

varicella infection;Congestive hepatopathy;Convulsion in childhood;Convulsions

local;Convulsive threshold lowered;Coombs positive haemolytic anaemia;Coronary artery

disease;Coronary artery embolism;Coronary artery thrombosis;Coronary bypass

thrombosis;Coronavirus infection;Coronavirus test;Coronavirus test negative;Coronavirus

test positive;Corpus callosotomy;Cough;Cough variant asthma;COVID-19;COVID-19

immunisation;COVID-19 pneumonia;COVID-19 prophylaxis;COVID-19 treatment;Cranial

nerve disorder;Cranial nerve palsies multiple;Cranial nerve paralysis;CREST

syndrome;Crohn's disease;Cryofibrinogenaemia;Cryoglobulinaemia;CSF oligoclonal band

present;CSWS syndrome;Cutaneous amyloidosis;Cutaneous lupus erythematosus;Cutaneous

sarcoidosis;Cutaneous vasculitis;Cyanosis;Cyclic neutropenia;Cystitis interstitial;Cytokine

release syndrome;Cytokine storm;De novo purine synthesis inhibitors associated acute

inflammatory syndrome;Death neonatal;Deep vein thrombosis;Deep vein thrombosis

postoperative;Deficiency of bile secretion;Deja vu;Demyelinating

polyneuropathy;Demyelination;Dermatitis;Dermatitis bullous;Dermatitis

herpetiformis;Dermatomyositis;Device embolisation;Device related thrombosis;Diabetes

mellitus;Diabetic ketoacidosis;Diabetic mastopathy;Dialysis amyloidosis;Dialysis membrane

reaction;Diastolic hypotension;Diffuse vasculitis;Digital pitting scar;Disseminated

intravascular coagulation;Disseminated intravascular coagulation in newborn;Disseminated

neonatal herpes simplex;Disseminated varicella;Disseminated varicella zoster vaccine virus

infection;Disseminated varicella zoster virus infection;DNA antibody positive;Double cortex

syndrome;Double stranded DNA antibody positive;Dreamy state;Dressler's syndrome;Drop

attacks;Drug withdrawal convulsions;Dyspnoea;Early infantile epileptic encephalopathy with

burst-suppression;Eclampsia;Eczema herpeticum;Embolia cutis medicamentosa;Embolic

cerebellar infarction;Embolic cerebral infarction;Embolic pneumonia;Embolic

stroke;Embolism;Embolism arterial;Embolism venous;Encephalitis;Encephalitis

allergic;Encephalitis autoimmune;Encephalitis brain stem;Encephalitis

haemorrhagic;Encephalitis periaxialis diffusa;Encephalitis post

immunisation;Encephalomyelitis;Encephalopathy;Endocrine disorder;Endocrine

ophthalmopathy;Endotracheal intubation;Enteritis;Enteritis leukopenic;Enterobacter

pneumonia;Enterocolitis;Enteropathic spondylitis;Eosinopenia;Eosinophilic

Page 32 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (

GMT)

FDA-CBER-2021-5683-0000085

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

CONFIDENTIAL

Page 4

fasciitis;Eosinophilic granulomatosis with polyangiitis;Eosinophilic

oesophagitis;Epidermolysis;Epilepsy;Epilepsy surgery;Epilepsy with myoclonic-atonic

seizures;Epileptic aura;Epileptic psychosis;Erythema;Erythema induratum;Erythema

multiforme;Erythema nodosum;Evans syndrome;Exanthema subitum;Expanded disability

status scale score decreased;Expanded disability status scale score increased;Exposure to

communicable disease;Exposure to SARS-CoV-2;Eye oedema;Eye pruritus;Eye

swelling;Eyelid oedema;Face oedema;Facial paralysis;Facial paresis;Faciobrachial dystonic

seizure;Fat embolism;Febrile convulsion;Febrile infection-related epilepsy syndrome;Febrile

neutropenia;Felty's syndrome;Femoral artery embolism;Fibrillary

glomerulonephritis;Fibromyalgia;Flushing;Foaming at mouth;Focal cortical resection;Focal

dyscognitive seizures;Foetal distress syndrome;Foetal placental thrombosis;Foetor

hepaticus;Foreign body embolism;Frontal lobe epilepsy;Fulminant type 1 diabetes

mellitus;Galactose elimination capacity test abnormal;Galactose elimination capacity test

decreased;Gamma-glutamyltransferase abnormal;Gamma-glutamyltransferase

increased;Gastritis herpes;Gastrointestinal amyloidosis;Gelastic seizure;Generalised onset

non-motor seizure;Generalised tonic-clonic seizure;Genital herpes;Genital herpes

simplex;Genital herpes zoster;Giant cell arteritis;Glomerulonephritis;Glomerulonephritis

membranoproliferative;Glomerulonephritis membranous;Glomerulonephritis rapidly

progressive;Glossopharyngeal nerve paralysis;Glucose transporter type 1 deficiency

syndrome;Glutamate dehydrogenase increased;Glycocholic acid increased;GM2

gangliosidosis;Goodpasture's syndrome;Graft

thrombosis;Granulocytopenia;Granulocytopenia neonatal;Granulomatosis with

polyangiitis;Granulomatous dermatitis;Grey matter heterotopia;Guanase increased;Guillain-

Barre syndrome;Haemolytic anaemia;Haemophagocytic

lymphohistiocytosis;Haemorrhage;Haemorrhagic ascites;Haemorrhagic

disorder;Haemorrhagic pneumonia;Haemorrhagic varicella syndrome;Haemorrhagic

vasculitis;Hantavirus pulmonary infection;Hashimoto's

encephalopathy;Hashitoxicosis;Hemimegalencephaly;Henoch-Schonlein purpura;Henoch-

Schonlein purpura nephritis;Hepaplastin abnormal;Hepaplastin decreased;Heparin-induced

thrombocytopenia;Hepatic amyloidosis;Hepatic artery embolism;Hepatic artery flow

decreased;Hepatic artery thrombosis;Hepatic enzyme abnormal;Hepatic enzyme

decreased;Hepatic enzyme increased;Hepatic fibrosis marker abnormal;Hepatic fibrosis

marker increased;Hepatic function abnormal;Hepatic hydrothorax;Hepatic

hypertrophy;Hepatic hypoperfusion;Hepatic lymphocytic infiltration;Hepatic mass;Hepatic

pain;Hepatic sequestration;Hepatic vascular resistance increased;Hepatic vascular

thrombosis;Hepatic vein embolism;Hepatic vein thrombosis;Hepatic venous pressure

gradient abnormal;Hepatic venous pressure gradient increased;Hepatitis;Hepatobiliary scan

abnormal;Hepatomegaly;Hepatosplenomegaly;Hereditary angioedema with C1 esterase

inhibitor deficiency;Herpes dermatitis;Herpes gestationis;Herpes oesophagitis;Herpes

ophthalmic;Herpes pharyngitis;Herpes sepsis;Herpes simplex;Herpes simplex

cervicitis;Herpes simplex colitis;Herpes simplex encephalitis;Herpes simplex gastritis;Herpes

simplex hepatitis;Herpes simplex meningitis;Herpes simplex meningoencephalitis;Herpes

simplex meningomyelitis;Herpes simplex necrotising retinopathy;Herpes simplex

oesophagitis;Herpes simplex otitis externa;Herpes simplex pharyngitis;Herpes simplex

pneumonia;Herpes simplex reactivation;Herpes simplex sepsis;Herpes simplex

viraemia;Herpes simplex virus conjunctivitis neonatal;Herpes simplex visceral;Herpes virus

Page 33 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (

GMT)

FDA-CBER-2021-5683-0000086

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

CONFIDENTIAL

Page 5

infection;Herpes zoster;Herpes zoster cutaneous disseminated;Herpes zoster infection

neurological;Herpes zoster meningitis;Herpes zoster meningoencephalitis;Herpes zoster

meningomyelitis;Herpes zoster meningoradiculitis;Herpes zoster necrotising

retinopathy;Herpes zoster oticus;Herpes zoster pharyngitis;Herpes zoster

reactivation;Herpetic radiculopathy;Histone antibody positive;Hoigne's syndrome;Human

herpesvirus 6 encephalitis;Human herpesvirus 6 infection;Human herpesvirus 6 infection

reactivation;Human herpesvirus 7 infection;Human herpesvirus 8

infection;Hyperammonaemia;Hyperbilirubinaemia;Hypercholia;Hypergammaglobulinaemia

benign monoclonal;Hyperglycaemic seizure;Hypersensitivity;Hypersensitivity

vasculitis;Hyperthyroidism;Hypertransaminasaemia;Hyperventilation;Hypoalbuminaemia;H

ypocalcaemic seizure;Hypogammaglobulinaemia;Hypoglossal nerve paralysis;Hypoglossal

nerve paresis;Hypoglycaemic seizure;Hyponatraemic seizure;Hypotension;Hypotensive

crisis;Hypothenar hammer syndrome;Hypothyroidism;Hypoxia;Idiopathic CD4

lymphocytopenia;Idiopathic generalised epilepsy;Idiopathic interstitial pneumonia;Idiopathic

neutropenia;Idiopathic pulmonary fibrosis;IgA nephropathy;IgM nephropathy;IIIrd nerve

paralysis;IIIrd nerve paresis;Iliac artery embolism;Immune thrombocytopenia;Immunemediated

adverse reaction;Immune-mediated cholangitis;Immune-mediated

cholestasis;Immune-mediated cytopenia;Immune-mediated encephalitis;Immune-mediated

encephalopathy;Immune-mediated endocrinopathy;Immune-mediated enterocolitis;Immunemediated

gastritis;Immune-mediated hepatic disorder;Immune-mediated hepatitis;Immunemediated

hyperthyroidism;Immune-mediated hypothyroidism;Immune-mediated

myocarditis;Immune-mediated myositis;Immune-mediated nephritis;Immune-mediated

neuropathy;Immune-mediated pancreatitis;Immune-mediated pneumonitis;Immune-mediated

renal disorder;Immune-mediated thyroiditis;Immune-mediated uveitis;Immunoglobulin G4

related disease;Immunoglobulins abnormal;Implant site thrombosis;Inclusion body

myositis;Infantile genetic agranulocytosis;Infantile spasms;Infected vasculitis;Infective

thrombosis;Inflammation;Inflammatory bowel disease;Infusion site thrombosis;Infusion site

vasculitis;Injection site thrombosis;Injection site urticaria;Injection site vasculitis;Instillation

site thrombosis;Insulin autoimmune syndrome;Interstitial granulomatous

dermatitis;Interstitial lung disease;Intracardiac mass;Intracardiac thrombus;Intracranial

pressure increased;Intrapericardial thrombosis;Intrinsic factor antibody abnormal;Intrinsic

factor antibody positive;IPEX syndrome;Irregular breathing;IRVAN syndrome;IVth nerve

paralysis;IVth nerve paresis;JC polyomavirus test positive;JC virus CSF test positive;Jeavons

syndrome;Jugular vein embolism;Jugular vein thrombosis;Juvenile idiopathic

arthritis;Juvenile myoclonic epilepsy;Juvenile polymyositis;Juvenile psoriatic

arthritis;Juvenile spondyloarthritis;Kaposi sarcoma inflammatory cytokine

syndrome;Kawasaki's disease;Kayser-Fleischer ring;Keratoderma blenorrhagica;Ketosisprone

diabetes mellitus;Kounis syndrome;Lafora's myoclonic epilepsy;Lambl's

excrescences;Laryngeal dyspnoea;Laryngeal oedema;Laryngeal rheumatoid

arthritis;Laryngospasm;Laryngotracheal oedema;Latent autoimmune diabetes in adults;LE

cells present;Lemierre syndrome;Lennox-Gastaut syndrome;Leucine aminopeptidase

increased;Leukoencephalomyelitis;Leukoencephalopathy;Leukopenia;Leukopenia

neonatal;Lewis-Sumner syndrome;Lhermitte's sign;Lichen planopilaris;Lichen planus;Lichen

sclerosus;Limbic encephalitis;Linear IgA disease;Lip oedema;Lip swelling;Liver function

test abnormal;Liver function test decreased;Liver function test increased;Liver

induration;Liver injury;Liver iron concentration abnormal;Liver iron concentration

Page 34 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (

GMT)

FDA-CBER-2021-5683-0000087

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

CONFIDENTIAL

Page 6

increased;Liver opacity;Liver palpable;Liver sarcoidosis;Liver scan abnormal;Liver

tenderness;Low birth weight baby;Lower respiratory tract herpes infection;Lower respiratory

tract infection;Lower respiratory tract infection viral;Lung abscess;Lupoid hepatic

cirrhosis;Lupus cystitis;Lupus encephalitis;Lupus endocarditis;Lupus enteritis;Lupus

hepatitis;Lupus myocarditis;Lupus myositis;Lupus nephritis;Lupus pancreatitis;Lupus

pleurisy;Lupus pneumonitis;Lupus vasculitis;Lupus-like syndrome;Lymphocytic

hypophysitis;Lymphocytopenia neonatal;Lymphopenia;MAGIC syndrome;Magnetic

resonance imaging liver abnormal;Magnetic resonance proton density fat fraction

measurement;Mahler sign;Manufacturing laboratory analytical testing issue;Manufacturing

materials issue;Manufacturing production issue;Marburg's variant multiple

sclerosis;Marchiafava-Bignami disease;Marine Lenhart syndrome;Mastocytic

enterocolitis;Maternal exposure during pregnancy;Medical device site thrombosis;Medical

device site vasculitis;MELAS syndrome;Meningitis;Meningitis aseptic;Meningitis

herpes;Meningoencephalitis herpes simplex neonatal;Meningoencephalitis

herpetic;Meningomyelitis herpes;MERS-CoV test;MERS-CoV test negative;MERS-CoV test

positive;Mesangioproliferative glomerulonephritis;Mesenteric artery embolism;Mesenteric

artery thrombosis;Mesenteric vein thrombosis;Metapneumovirus infection;Metastatic

cutaneous Crohn's disease;Metastatic pulmonary

embolism;Microangiopathy;Microembolism;Microscopic polyangiitis;Middle East

respiratory syndrome;Migraine-triggered seizure;Miliary pneumonia;Miller Fisher

syndrome;Mitochondrial aspartate aminotransferase increased;Mixed connective tissue

disease;Model for end stage liver disease score abnormal;Model for end stage liver disease

score increased;Molar ratio of total branched-chain amino acid to tyrosine;Molybdenum

cofactor deficiency;Monocytopenia;Mononeuritis;Mononeuropathy

multiplex;Morphoea;Morvan syndrome;Mouth swelling;Moyamoya disease;Multifocal

motor neuropathy;Multiple organ dysfunction syndrome;Multiple sclerosis;Multiple sclerosis

relapse;Multiple sclerosis relapse prophylaxis;Multiple subpial transection;Multisystem

inflammatory syndrome in children;Muscular sarcoidosis;Myasthenia gravis;Myasthenia

gravis crisis;Myasthenia gravis neonatal;Myasthenic syndrome;Myelitis;Myelitis

transverse;Myocardial infarction;Myocarditis;Myocarditis post infection;Myoclonic

epilepsy;Myoclonic epilepsy and ragged-red fibres;Myokymia;Myositis;Narcolepsy;Nasal

herpes;Nasal obstruction;Necrotising herpetic retinopathy;Neonatal Crohn's disease;Neonatal

epileptic seizure;Neonatal lupus erythematosus;Neonatal mucocutaneous herpes

simplex;Neonatal pneumonia;Neonatal seizure;Nephritis;Nephrogenic systemic

fibrosis;Neuralgic amyotrophy;Neuritis;Neuritis cranial;Neuromyelitis optica pseudo

relapse;Neuromyelitis optica spectrum disorder;Neuromyotonia;Neuronal

neuropathy;Neuropathy peripheral;Neuropathy, ataxia, retinitis pigmentosa

syndrome;Neuropsychiatric lupus;Neurosarcoidosis;Neutropenia;Neutropenia

neonatal;Neutropenic colitis;Neutropenic infection;Neutropenic sepsis;Nodular rash;Nodular

vasculitis;Noninfectious myelitis;Noninfective encephalitis;Noninfective

encephalomyelitis;Noninfective oophoritis;Obstetrical pulmonary embolism;Occupational

exposure to communicable disease;Occupational exposure to SARS-CoV-2;Ocular

hyperaemia;Ocular myasthenia;Ocular pemphigoid;Ocular sarcoidosis;Ocular

vasculitis;Oculofacial paralysis;Oedema;Oedema blister;Oedema due to hepatic

disease;Oedema mouth;Oesophageal achalasia;Ophthalmic artery thrombosis;Ophthalmic

herpes simplex;Ophthalmic herpes zoster;Ophthalmic vein thrombosis;Optic neuritis;Optic

Page 35 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (

GMT)

FDA-CBER-2021-5683-0000088

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

CONFIDENTIAL

Page 7

neuropathy;Optic perineuritis;Oral herpes;Oral lichen planus;Oropharyngeal

oedema;Oropharyngeal spasm;Oropharyngeal swelling;Osmotic demyelination

syndrome;Ovarian vein thrombosis;Overlap syndrome;Paediatric autoimmune

neuropsychiatric disorders associated with streptococcal infection;Paget-Schroetter

syndrome;Palindromic rheumatism;Palisaded neutrophilic granulomatous

dermatitis;Palmoplantar keratoderma;Palpable

purpura;Pancreatitis;Panencephalitis;Papillophlebitis;Paracancerous pneumonia;Paradoxical

embolism;Parainfluenzae viral laryngotracheobronchitis;Paraneoplastic

dermatomyositis;Paraneoplastic pemphigus;Paraneoplastic thrombosis;Paresis cranial

nerve;Parietal cell antibody positive;Paroxysmal nocturnal haemoglobinuria;Partial

seizures;Partial seizures with secondary generalisation;Patient isolation;Pelvic venous

thrombosis;Pemphigoid;Pemphigus;Penile vein thrombosis;Pericarditis;Pericarditis

lupus;Perihepatic discomfort;Periorbital oedema;Periorbital swelling;Peripheral artery

thrombosis;Peripheral embolism;Peripheral ischaemia;Peripheral vein thrombus

extension;Periportal oedema;Peritoneal fluid protein abnormal;Peritoneal fluid protein

decreased;Peritoneal fluid protein increased;Peritonitis lupus;Pernicious anaemia;Petit mal

epilepsy;Pharyngeal oedema;Pharyngeal swelling;Pityriasis lichenoides et varioliformis

acuta;Placenta praevia;Pleuroparenchymal fibroelastosis;Pneumobilia;Pneumonia;Pneumonia

adenoviral;Pneumonia cytomegaloviral;Pneumonia herpes viral;Pneumonia

influenzal;Pneumonia measles;Pneumonia mycoplasmal;Pneumonia necrotising;Pneumonia

parainfluenzae viral;Pneumonia respiratory syncytial viral;Pneumonia viral;POEMS

syndrome;Polyarteritis nodosa;Polyarthritis;Polychondritis;Polyglandular autoimmune

syndrome type I;Polyglandular autoimmune syndrome type II;Polyglandular autoimmune

syndrome type III;Polyglandular disorder;Polymicrogyria;Polymyalgia

rheumatica;Polymyositis;Polyneuropathy;Polyneuropathy idiopathic progressive;Portal

pyaemia;Portal vein embolism;Portal vein flow decreased;Portal vein pressure

increased;Portal vein thrombosis;Portosplenomesenteric venous thrombosis;Post procedural

hypotension;Post procedural pneumonia;Post procedural pulmonary embolism;Post stroke

epilepsy;Post stroke seizure;Post thrombotic retinopathy;Post thrombotic syndrome;Post viral

fatigue syndrome;Postictal headache;Postictal paralysis;Postictal psychosis;Postictal

state;Postoperative respiratory distress;Postoperative respiratory failure;Postoperative

thrombosis;Postpartum thrombosis;Postpartum venous thrombosis;Postpericardiotomy

syndrome;Post-traumatic epilepsy;Postural orthostatic tachycardia syndrome;Precerebral

artery thrombosis;Pre-eclampsia;Preictal state;Premature labour;Premature

menopause;Primary amyloidosis;Primary biliary cholangitis;Primary progressive multiple

sclerosis;Procedural shock;Proctitis herpes;Proctitis ulcerative;Product availability

issue;Product distribution issue;Product supply issue;Progressive facial

hemiatrophy;Progressive multifocal leukoencephalopathy;Progressive multiple

sclerosis;Progressive relapsing multiple sclerosis;Prosthetic cardiac valve

thrombosis;Pruritus;Pruritus allergic;Pseudovasculitis;Psoriasis;Psoriatic

arthropathy;Pulmonary amyloidosis;Pulmonary artery thrombosis;Pulmonary

embolism;Pulmonary fibrosis;Pulmonary haemorrhage;Pulmonary microemboli;Pulmonary

oil microembolism;Pulmonary renal syndrome;Pulmonary sarcoidosis;Pulmonary

sepsis;Pulmonary thrombosis;Pulmonary tumour thrombotic microangiopathy;Pulmonary

vasculitis;Pulmonary veno-occlusive disease;Pulmonary venous thrombosis;Pyoderma

gangrenosum;Pyostomatitis vegetans;Pyrexia;Quarantine;Radiation leukopenia;Radiculitis

Page 36 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (

GMT)

FDA-CBER-2021-5683-0000089

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

CONFIDENTIAL

Page 8

brachial;Radiologically isolated syndrome;Rash;Rash erythematous;Rash pruritic;Rasmussen

encephalitis;Raynaud's phenomenon;Reactive capillary endothelial proliferation;Relapsing

multiple sclerosis;Relapsing-remitting multiple sclerosis;Renal amyloidosis;Renal

arteritis;Renal artery thrombosis;Renal embolism;Renal failure;Renal vascular

thrombosis;Renal vasculitis;Renal vein embolism;Renal vein thrombosis;Respiratory

arrest;Respiratory disorder;Respiratory distress;Respiratory failure;Respiratory

paralysis;Respiratory syncytial virus bronchiolitis;Respiratory syncytial virus

bronchitis;Retinal artery embolism;Retinal artery occlusion;Retinal artery thrombosis;Retinal

vascular thrombosis;Retinal vasculitis;Retinal vein occlusion;Retinal vein thrombosis;Retinol

binding protein decreased;Retinopathy;Retrograde portal vein flow;Retroperitoneal

fibrosis;Reversible airways obstruction;Reynold's syndrome;Rheumatic brain

disease;Rheumatic disorder;Rheumatoid arthritis;Rheumatoid factor increased;Rheumatoid

factor positive;Rheumatoid factor quantitative increased;Rheumatoid lung;Rheumatoid

neutrophilic dermatosis;Rheumatoid nodule;Rheumatoid nodule removal;Rheumatoid

scleritis;Rheumatoid vasculitis;Saccadic eye movement;SAPHO

syndrome;Sarcoidosis;SARS-CoV-1 test;SARS-CoV-1 test negative;SARS-CoV-1 test

positive;SARS-CoV-2 antibody test;SARS-CoV-2 antibody test negative;SARS-CoV-2

antibody test positive;SARS-CoV-2 carrier;SARS-CoV-2 sepsis;SARS-CoV-2 test;SARSCoV-

2 test false negative;SARS-CoV-2 test false positive;SARS-CoV-2 test negative;SARSCoV-

2 test positive;SARS-CoV-2 viraemia;Satoyoshi

syndrome;Schizencephaly;Scleritis;Sclerodactylia;Scleroderma;Scleroderma associated

digital ulcer;Scleroderma renal crisis;Scleroderma-like reaction;Secondary

amyloidosis;Secondary cerebellar degeneration;Secondary progressive multiple

sclerosis;Segmented hyalinising vasculitis;Seizure;Seizure anoxic;Seizure cluster;Seizure

like phenomena;Seizure prophylaxis;Sensation of foreign body;Septic embolus;Septic

pulmonary embolism;Severe acute respiratory syndrome;Severe myoclonic epilepsy of

infancy;Shock;Shock symptom;Shrinking lung syndrome;Shunt thrombosis;Silent

thyroiditis;Simple partial seizures;Sjogren's syndrome;Skin swelling;SLE arthritis;Smooth

muscle antibody positive;Sneezing;Spinal artery embolism;Spinal artery thrombosis;Splenic

artery thrombosis;Splenic embolism;Splenic thrombosis;Splenic vein

thrombosis;Spondylitis;Spondyloarthropathy;Spontaneous heparin-induced

thrombocytopenia syndrome;Status epilepticus;Stevens-Johnson syndrome;Stiff leg

syndrome;Stiff person syndrome;Stillbirth;Still's disease;Stoma site thrombosis;Stoma site

vasculitis;Stress cardiomyopathy;Stridor;Subacute cutaneous lupus erythematosus;Subacute

endocarditis;Subacute inflammatory demyelinating polyneuropathy;Subclavian artery

embolism;Subclavian artery thrombosis;Subclavian vein thrombosis;Sudden unexplained

death in epilepsy;Superior sagittal sinus thrombosis;Susac's syndrome;Suspected COVID-

19;Swelling;Swelling face;Swelling of eyelid;Swollen tongue;Sympathetic

ophthalmia;Systemic lupus erythematosus;Systemic lupus erythematosus disease activity

index abnormal;Systemic lupus erythematosus disease activity index decreased;Systemic

lupus erythematosus disease activity index increased;Systemic lupus erythematosus

rash;Systemic scleroderma;Systemic sclerosis

pulmonary;Tachycardia;Tachypnoea;Takayasu's arteritis;Temporal lobe epilepsy;Terminal

ileitis;Testicular autoimmunity;Throat tightness;Thromboangiitis

obliterans;Thrombocytopenia;Thrombocytopenic

purpura;Thrombophlebitis;Thrombophlebitis migrans;Thrombophlebitis

Page 37 090177e196ea1800\Approved\Approved On: 30-Apr-2021 09:26 (

GMT)

FDA-CBER-2021-5683-0000090

BNT162b2

5.3.6 Cumulative Analysis of Post-authorization Adverse Event Reports

CONFIDENTIAL

Page 9

neonatal;Thrombophlebitis septic;Thrombophlebitis superficial;Thromboplastin antibody

positive;Thrombosis;Thrombosis corpora cavernosa;Thrombosis in device;Thrombosis

mesenteric vessel;Thrombotic cerebral infarction;Thrombotic microangiopathy;Thrombotic

stroke;Thrombotic thrombocytopenic purpura;Thyroid disorder;Thyroid stimulating

immunoglobulin increased;Thyroiditis;Tongue amyloidosis;Tongue biting;Tongue

oedema;Tonic clonic movements;Tonic convulsion;Tonic posturing;Topectomy;Total bile

acids increased;Toxic epidermal necrolysis;Toxic leukoencephalopathy;Toxic oil

syndrome;Tracheal obstruction;Tracheal oedema;Tracheobronchitis;Tracheobronchitis

mycoplasmal;Tracheobronchitis viral;Transaminases abnormal;Transaminases

increased;Transfusion-related alloimmune neutropenia;Transient epileptic

amnesia;Transverse sinus thrombosis;Trigeminal nerve paresis;Trigeminal

neuralgia;Trigeminal palsy;Truncus coeliacus thrombosis;Tuberous sclerosis

complex;Tubulointerstitial nephritis and uveitis syndrome;Tumefactive multiple

sclerosis;Tumour embolism;Tumour thrombosis;Type 1 diabetes mellitus;Type I

hypersensitivity;Type III immune complex mediated reaction;Uhthoff's

phenomenon;Ulcerative keratitis;Ultrasound liver abnormal;Umbilical cord

thrombosis;Uncinate fits;Undifferentiated connective tissue disease;Upper airway

obstruction;Urine bilirubin increased;Urobilinogen urine decreased;Urobilinogen urine

increased;Urticaria;Urticaria papular;Urticarial vasculitis;Uterine

rupture;Uveitis;Vaccination site thrombosis;Vaccination site vasculitis;Vagus nerve

paralysis;Varicella;Varicella keratitis;Varicella post vaccine;Varicella zoster

gastritis;Varicella zoster oesophagitis;Varicella zoster pneumonia;Varicella zoster

sepsis;Varicella zoster virus infection;Vasa praevia;Vascular graft thrombosis;Vascular

pseudoaneurysm thrombosis;Vascular purpura;Vascular stent thrombosis;Vasculitic

rash;Vasculitic ulcer;Vasculitis;Vasculitis gastrointestinal;Vasculitis necrotising;Vena cava

embolism;Vena cava thrombosis;Venous intravasation;Venous recanalisation;Venous

thrombosis;Venous thrombosis in pregnancy;Venous thrombosis limb;Venous thrombosis

neonatal;Vertebral artery thrombosis;Vessel puncture site thrombosis;Visceral venous

thrombosis;VIth nerve paralysis;VIth nerve paresis;Vitiligo;Vocal cord paralysis;Vocal cord

paresis;Vogt-Koyanagi-Harada disease;Warm type haemolytic anaemia;Wheezing;White

nipple sign;XIth nerve paralysis;X-ray hepatobiliary abnormal;Young's syndrome;Zika virus associated Guillain Barre Syndrome